KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Current Deferred Revenue (2021 - 2024)

Travere Therapeutics (TVTX) has disclosed Current Deferred Revenue for 4 consecutive years, with $2.8 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Current Deferred Revenue fell 68.48% year-over-year to $2.8 million, compared with a TTM value of $2.8 million through Dec 2024, down 68.48%, and an annual FY2024 reading of $2.8 million, down 68.48% over the prior year.
  • Current Deferred Revenue was $2.8 million for Q4 2024 at Travere Therapeutics, down from $3.8 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $43.0 million in Q3 2021 and bottomed at $2.8 million in Q4 2024.
  • Average Current Deferred Revenue over 4 years is $14.2 million, with a median of $10.6 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue crashed 73.53% in 2022, then decreased 18.07% in 2023.
  • Year by year, Current Deferred Revenue stood at $36.6 million in 2021, then crashed by 37.49% to $22.9 million in 2022, then crashed by 61.01% to $8.9 million in 2023, then crashed by 68.48% to $2.8 million in 2024.
  • Business Quant data shows Current Deferred Revenue for TVTX at $2.8 million in Q4 2024, $3.8 million in Q3 2024, and $5.4 million in Q2 2024.